logo
Share SHARE
FONT-SIZE Plus   Neg

Rexahn Gets European Patent For Cancer Drug Archexin

Rexahn Pharmaceuticals, Inc. (RNN) said Thursday that the European Patent Office has granted the company a patent, EP 1546180, for its clinical development candidate Archexin and its use for inhibiting the activated form of Akt-1 for the treatment of cancer.

Having successfully completed a Phase IIa clinical trial of Archexin in metastatic pancreatic cancer, Rexahn has conducted an extensive scientific, clinical and business analysis of other potential indications for additional Phase IIa clinical trials with the drug.

Rexahn is now working with key clinical opinion leaders to finalize the design of a Phase IIa clinical trial in a selected tumor type and plans on updating investors on the tumor type selection and Phase IIa trial timeline in the fourth quarter of 2013.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Struggling fast-food giant McDonald's is trying to woo back customers to its stores with a new concept called "Experience of the Future." According to reports, as part of its "Experience of the Future" initiative McDonald's is planning to upgrade and renovate its restaurants that will provide modern... Facebook might be launching smart speakers with a touch panel next year. The touch screen could be used for 15-inch display of imageries. According to reports Facebook has already begun the pilot production in China. The new device is expected to be launched in the first quarter of 2018. Britain is the latest nation to announce that it will end the sale of new petrol and diesel cars in an effort to reduce air pollution. Britain said it will ban the sale of new petrol and diesel cars from 2040. In early July, France said it plans to end sales of all petrol and diesel vehicles in the country by 2040 as part of a plan to meet its targets under the Paris climate accord.
comments powered by Disqus
Follow RTT